Discussion about this post

User's avatar
Neural Foundry's avatar

The $11 billion price tag for Avidity represents a massive premium but signals Novartis's commitment to dominating the RNA therapeutics space. Their AOC platform targeting muscle diseases fills a critical gap in Novartis's pipeline, especially with the myotonic dystrophy and Pompe disease programs advancing. This aquisition could position them ahead of competitors in a therapeutic area with limited effective treatments.

Expand full comment
Noble Investing's avatar

Interesting that many small companies like Chegg and iRobot will remain standalone public companies.

While high risk, could provide compelling returns over the next few years if successful.

Expand full comment
3 more comments...

No posts